Is ORXOY or NOBL a better dividend investment in 2026?

ORXOY currently yields 71.43% with a 5% 5-year dividend growth rate. NOBL yields 2.14% with 5% growth. The better choice depends on your goal: ORXOY offers higher current income.

What is the dividend yield difference between ORXOY and NOBL?

ORXOY has a forward dividend yield of 71.43% ($2.00/share annually). NOBL yields 2.14% ($2.27/share annually). The yield gap is 69.29 percentage points.

Home › Compare › ORXOY vs NOBL

ORXOY vs NOBL: Dividend Comparison 2026

ORXOY yields 71.43% · NOBL yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ORXOY wins by $1.10M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ORXOY

● Live price

71.43%

Share price

$2.80

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1.12M

Annual income

$299,297.66

Full ORXOY calculator →

NOBL

● Live price

2.14%

Share price

$106.01

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.8K

Annual income

$246.19

Full NOBL calculator →

Portfolio growth — ORXOY vs NOBL

📍 ORXOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ORXOY	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ORXOY + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ORXOY pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOY

Annual income on $10K today (after 15% tax)

$6,071.43/yr

After 10yr DRIP, annual income (after tax)

$254,403.01/yr

NOBL

Annual income on $10K today (after 15% tax)

$182.19/yr

After 10yr DRIP, annual income (after tax)

$209.26/yr

At 15% tax rate, ORXOY beats the other by $254,193.75/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOY + NOBL for your $10,000?

ORXOY: 50%NOBL: 50%

100% NOBL50/50100% ORXOY

Portfolio after 10yr

$573.2K

Annual income

$149,771.92/yr

Blended yield

26.13%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOY buys

NOBL buys

No recent congressional trades found for ORXOY or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricORXOYNOBL

Forward yield	71.43% ✓	2.14%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$1.12M	$22.8K ✓
Annual income after 10y	$299,297.66 ✓	$246.19
Total dividends collected	$960.2K ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ORXOY vs NOBL ($10,000, DRIP)

Year	ORXOY Portfolio	ORXOY Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$17,843	$7,142.86	$10,914	$214.34	+$6.9K → ORXOY
2	$31,003	$11,911.12	$11,897	$218.63	+$19.1K → ORXOY
3	$52,515	$19,342.29	$12,952	$222.72	+$39.6K → ORXOY
4	$86,812	$30,620.19	$14,086	$226.62	+$72.7K → ORXOY
5	$140,194	$47,305.90	$15,302	$230.33	+$124.9K → ORXOY
6	$221,406	$71,397.66	$16,607	$233.85	+$204.8K → ORXOY
7	$342,284	$105,380.00	$18,007	$237.18	+$324.3K → ORXOY
8	$518,499	$152,255.26	$19,508	$240.35	+$499.0K → ORXOY
9	$770,345	$215,550.93	$21,116	$243.35	+$749.2K → ORXOY
10	$1,123,567	$299,297.66	$22,841	$246.19	+$1.10M → ORXOY

ORXOY vs NOBL: Complete Analysis 2026

ORXOY — Stock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOY Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this ORXOY vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOY vs SCHD ORXOY vs JEPI ORXOY vs O ORXOY vs KO ORXOY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.